Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Colitis, Ulcerative;Crohn Disease, Date of authorisation: 22/05/2014, Revision: 25, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Respiratory syncytial virus stabilised prefusion F subunit vaccine, decision type: , therapeutic area: , PIP number: P/0058/2023

Opinion/decision on a Paediatric investigation plan (PIP): Exagamglogene autotemcel, decision type: , therapeutic area: , PIP number: P/0046/2023

Human medicines European public assessment report (EPAR): Silodosin Recordati, silodosin, Prostatic Hyperplasia, Date of authorisation: 07/01/2019, Revision: 2, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Garadacimab, decision type: , therapeutic area: , PIP number: P/0048/2023

Opinion/decision on a Paediatric investigation plan (PIP): diclofenac,orphenadrine (citrate), decision type: , therapeutic area: , PIP number: P/0036/2023

Opinion/decision on a Paediatric investigation plan (PIP): Tetanus toxoid, decision type: , therapeutic area: , PIP number: P/0043/2023

Opinion/decision on a Paediatric investigation plan (PIP): setanaxib, decision type: , therapeutic area: , PIP number: P/0032/2023

Opinion/decision on a Paediatric investigation plan (PIP): rivaroxaban,Acetylsalicylic acid, decision type: , therapeutic area: , PIP number: P/0042/2023

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Lymphoma, Follicular, Date of authorisation: 03/06/2022, Revision: 2, Status: Authorised